Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Other Non-Current Assets: 2019-2024

Historic Other Non-Current Assets for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to $5.8 million.

  • Kymera Therapeutics' Other Non-Current Assets rose 18.07% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 18.07%. This contributed to the annual value of $5.8 million for FY2024, which is 0.29% down from last year.
  • Latest data reveals that Kymera Therapeutics reported Other Non-Current Assets of $5.8 million as of FY2024, which was down 0.29% from $5.8 million recorded in FY2023.
  • Kymera Therapeutics' 5-year Other Non-Current Assets high stood at $6.1 million for FY2022, and its period low was $1.6 million during FY2020.
  • Over the past 3 years, Kymera Therapeutics' median Other Non-Current Assets value was $5.8 million (recorded in 2023), while the average stood at $5.9 million.
  • As far as peak fluctuations go, Kymera Therapeutics' Other Non-Current Assets declined by 10.43% in 2020, and later skyrocketed by 284.90% in 2021.
  • Over the past 5 years, Kymera Therapeutics' Other Non-Current Assets (Yearly) stood at $1.6 million in 2020, then skyrocketed by 284.90% to $6.1 million in 2021, then climbed by 0.23% to $6.1 million in 2022, then fell by 5.20% to $5.8 million in 2023, then dropped by 0.29% to $5.8 million in 2024.